The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives

Mon, 11th Oct 2021 10:59

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Cadence Minerals PLC, up 42% at 24.65 pence, 12-month range 11.1p-32.49p. Receives confirmation from its secured bank creditors that they have obtained approval from their credit committees for the proposed terms of a settlement agreement, paving the way for Cadence to vest an initial 20% in the Amapa iron ore project in Brazil. A joint venture between Cadence and Indo Sino Trade Pte Ltd will own 99.9% of DEV Mineracao SA, the owner of the Amapa project. "Today's announcement is a landmark for Amapa, both in terms of certainty for DEV employees, the wider Amapa community and for Cadence shareholders," says Chair Andrew Suckling.

----------

Reneuron Group PLC, up 31% at 123.80p, 12-month 70p-153.78p. The biotechnology company reports positive data that provides "clear pre-clinical proof-of-concept" that its novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases. "These results are a key milestone for our exosome delivery technology, establishing clear proof of concept in vivo, which more accurately imitates conditions for the targeted delivery of key neurological therapeutics into the human brain," says Chief Executive Olav Hellebo.

----------

Feedback PLC, up 16% at 0.8432p, 12-month range 0.6p-1.57p. The medical imaging software company signs memorandum of understanding with Quest Teleradiology Solutions - a teleradiology organisation with customers across India, the UK and throughout Africa - to develop strategic opportunities for Bleepa, its clinical communications platform, in the "large and growing" Indian healthcare market, the UK and internationally.

----------

Oracle Power PLC, up 15% at 0.385p, 12-month 0.3p-0.75p. The natural resources project developer signs non-exclusive co-operation agreement with PowerChina International Group Ltd to jointly develop a green hydrogen production facility in Pakistan. It is targeting 400 megawatt capacity hydrogen plant, with planned output of around 150,000 kilograms per day.

----------

AIM - LOSERS

----------

ASOS PLC, down 11% at 2,474p, 12-month range 2,300p-5,994.95p. The online fashion retailer posts jump in annual profit, but warns on year ahead and announces departure of chief executive. Adjusted pretax profit for the 2022 financial year expected between around GBP110 million to GBP140 million. This is well below the GBP193.6 million registered for the financial year just ended. ASOS shakes up board to "underpin delivery of the next phase of its global growth strategy". CEO Nick Beighton is stepping down after 12 years with ASOS, including six as CEO, and a search is underway for his replacement.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Nov 2019 16:07

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
23 Oct 2019 15:50

ReNeuron presents new data on CTX stem cell platform

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Wednesday that new data relating to its CTX stem cell platform was being presented at the 27th Annual Congress of the European Society of Gene and Cell Therapy in Barcelona.

Read more
23 Oct 2019 09:32

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

ReNeuron Shares Jump As Lead Cell Line Shows Further Potential

Read more
2 Oct 2019 15:15

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

ReNeuron Reports Mixed Results For Retinitis Pigmentosa Trial

Read more
21 Aug 2019 11:49

ReNeuron boosts scientific advisory board with three appointments

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced the appointment of professor Robert MacLaren, Dr Sally Temple and Dr José-Alain Sahel to its scientific advisory board on Wednesday.

Read more
14 Aug 2019 15:35

ReNeuron's New Cardiff University Venture Gets Research Grant

(Alliance News) - ReNeuron Group PLC on Wednesday said a new venture with Cardiff University has secured a UK government grant to research and develop new treatments for hard-to-target disorders a

Read more
14 Aug 2019 11:16

ReNeuron enters grant-funded partnership with University of Cardiff

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group is partnering with the University of Cardiff under a new grant-funded collaboration utilising its exosome-based drug delivery technology platform, it announced on Wednesday.

Read more
16 Jul 2019 12:16

ReNeuron Secures Patents For Its Exosome Technology Platform

(Alliance News) - ReNeuron Group PLC on Tuesday said it has expanded its intellectual property estate via the grant of patents, covering its exosome technology platform.The cell-based said

Read more
11 Jul 2019 11:36

ReNeuron Annual Loss Narrows On Finance Income And Licence Fee

(Alliance News) - ReNeuron Group PLC on Thursday said its loss narrowed in its most recent financial year after it received an exclusivity fee and increased finance income.Shares in were at

Read more
14 Jun 2019 15:49

ReNeuron wins 'Breakthrough of the Year' at European Mediscience Awards

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group has won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards, it announced on Friday.

Read more
8 May 2019 11:19

ReNeuron Expects Annual Results In Line With Views After Progress

LONDON (Alliance News) - ReNeuron Group PLC on Wednesday said it expects its annual results to be in line with the board's expectations as it made progress on several clinical cell-based also

Read more
8 May 2019 08:53

ReNeuron advances blindness and stroke therapy candidates

(Sharecast News) - Therapeutics outfit ReNeuron continued to trade in line with expectations throughout its recently wrapped up trading year, advancing both its human retinal progenitor cell therapy candidate and its CTX cell therapy candidate.

Read more
26 Apr 2019 12:09

ReNeuron upbeat on early data from retinitis pigmentosa trials

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced updated positive preliminary data in its ongoing phase 1 and 2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP), on Friday.

Read more
26 Apr 2019 09:58

ReNeuron Reports Positive Test Results For Blindness Treatment Therapy

LONDON (Alliance News) - ReNeuron Group PLC on Friday reported positive trial results for its human retinal progenitor cell therapy candidate for treating blindness-causing disease retinitis in up

Read more
11 Apr 2019 18:24

DIRECTOR DEALINGS: ReNeuron Chair And Other Board Members Buy Shares

LONDON (Alliance News) - ReNeuron Group PLC said a number of directors purchased shares on Thursday, including Non-Executive Chair John Berriman who bought 80,000 shares at 225 pence Thursday, in

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.